Methods of inhibiting presbyopia
AssigneeUniversity of Massachusetts
InventorsMurugappan Muthukumar, Zhaoyang Ou, Deniz Civay
Life of this patent
Estimating the term…
Abstract
Described herein are methods of inhibiting or reversing the progression of presbyopia in an eye by administering a βL-crystallin electrostatic interaction inhibitor. Presbyopia is caused by aggregation of the soluble crystalline lens proteins called the crystallins, particularly βL-crystallin. It has been found that the aggregation of βL-crystallin is an electrostatic phenomenon and that electrostatic interaction inhibitors can be employed to prevent the formation of βL-crystallin aggregates as well as to deaggregate already formed aggregates.
Claims12
A method of inhibiting or reversing the progression of presbyopia in an eye comprising
- contacting the eye with an effective presbyopia-inhibiting amount of an ophthalmic composition comprising at least one βL-crystallin electrostatic interaction inhibitor, wherein the βL-crystallin electrostatic interaction inhibitor comprises an organic salt containing a cation and an anion, wherein the cation and the anion are each independently an aliphatic group with the length of the aliphatic moiety of four to fifteen carbon atoms,
- wherein the βL-crystallin electrostatic interaction inhibitor comprises an ionic liquid.
A method of inhibiting or reversing the progression of presbyopia in an eye, comprising contacting the eye with an ophthalmic device comprising an an effective presbyopia—inhibiting amount of at least one βL-crystallin electrostatic interaction inhibitor, wherein the electrostatic interaction inhibitor is not a polypeptide,
- wherein the βL-crystallin electrostatic interaction inhibitor is an ammonium halide, an alkaline earth metal halide, potassium acetate, ammonium acetate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, calcium acetate, an alkylammonium salts, sodium formate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride, sodium succinate, or a combination thereof,
- wherein the ophthalmic device is a contact lens or a punctal plug.
A method of inhibiting or reversing the progression of age related degeneration of a crystalline lens in an eye comprising
- contacting the eye with an effective presbyopia -inhibiting amount of an ophthalmic composition comprising at least one βL-crystallin electrostatic interaction inhibitor, wherein the βL-crystallin electrostatic interaction inhibitor comprises an organic salt containing a cation and an anion, wherein the cation and the anion are each independently an aliphatic group with the length of the aliphatic moiety of four to fifteen carbon atoms,
- wherein the βL-crystallin electrostatic interaction inhibitor comprises an ionic liquid.
A method of inhibiting or reversing the progression of age related degeneration of a crystalline lens in an eye, comprising contacting the eye with an ophthalmic device comprising an effective degeneration -inhibiting amount of an ophthalmic composition comprising at least one βL-crystallin electrostatic interaction inhibitor, wherein the electrostatic interaction inhibitor is not a polypeptide,
- wherein the βL-crystallin electrostatic interaction inhibitor is an ammonium halide, an alkaline earth metal halide, potassium acetate, ammonium acetate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, calcium acetate, an alkylammonium salts, sodium formate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride, sodium succinate, or a combination thereof,
- wherein the ophthalmic device is a contact lens or a punctal plug.
Dependencies are inferred from the claim text.